| Vol. 14.41 – 20 October, 2022 |
| |
|
|
| Researchers evaluated the therapeutic potential of the secretome of human umbilical cord MSCs for dermatological diseases in adult human skin cells, ex vivo skin tissue, and a 3D skin model. [Cell and Tissue Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| SSEA-3(+) cells from human amniotic membrane MSCs were compared with human bone marrow-multilineage-differentiating stress-enduring (Muse) cells, in order to investigate similarities and differences of key charachteristics between the two cell types. [Scientific Reports] |
|
|
|
| The authors explored the available evidence for the therapeutic effect of human umbilical cord MSCs on early-stage traumatic osteonecrosis of the femoral head. [Journal of Orthopaedic Translation] |
|
|
|
| Scientists explored the potential pro-osteogenic differentiation effect of galangin, a flavonoid derived from Alpinia officinarum, on human amniotic MSCs and the underlying molecular mechanism. [European Journal of Pharmacology] |
|
|
|
| 3D gelatin microspheres (GM) had strong biocompatibility, and in comparison with two-dimensional adherent culturing, GM loading increased the cell viability, and proliferation ability of Wharton’s jelly MSCs. [Advances in Wound Care] |
|
|
|
| Investigators developed a modified differentiation process and identified a panel of GermlncRNAs related to germ-like cells. [Molecular Biology Reports] |
|
|
|
|
| The authors summarize the current standing and progress of human amniotic epithelial stem cells, amniotic MSCs, and amniotic fluid stem cells in the field of reproductive medicine. [Human Cell] |
|
|
|
| Investigators review the key studies which have utilized the ex vivo placenta perfusion model to study different aspects of such pregnancy pathologies. [Placenta] |
|
|
|
|
| Smart Immune SAS announced that SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using SmartImmune’s ProTcell™ platform, has entered clinical testing in a trial sponsored and led by Great Paris University Hospitals. [Smart Immune SAS] |
|
|
|
|
| January 29 – February 2, 2023 Banff, Alberta, Canada |
|
|
|
|
|
| Beth Israel Deaconess Medical Center – Boston, Massachusetts, United States |
|
|
|
| University of Maryland School of Medicine – Baltimore, Maryland, United States |
|
|
|
| STEMCELL Technologies – Vancouver, British Columbia, Canada |
|
|
|
| UCLA Jules Stein Eye Institute – Los Angeles, California, United States |
|
|
|
|
University of Colorado Denver – Aurora, Colorado, United States |
| | | | | | | | | |
|
|